Abstract:e16513 Background: Anti-PD-1 based therapies have been standard-of-care options in both the front-line and treatment refractory settings in RCC, but only 20%~60% of patients respond to ICBs. Current biomarkers often fail to predict benefit of ICBs, so new reliable biomarkers are urgently warranted. Methods: Genomic and transcriptomic data were collected from 3 different ICB-treated RCC cohorts, including Miao et al. (n=53, WES), CheckMate (CM, n=261, WES; n=181, RNA-Seq) and JAVELIN (n=354, RNA-Seq) cohorts. Hallmark pathways downloaded from MSigDB database were used to screened for defective pathways that correlated with PFS using WES data of Miao et al. and CM cohorts. A defective pathway was defined as detecting at least one variant. Enrichment scores were calculated using RNA-seq data of CM cohort based on 28 immune cells gene sets provided by Charoentong et al. Immune cell signatures (ICSs) related to PFS were screened out using cox regression analysis. The selected pathways and ICSs were combined to develop a logistic regression model (10-fold cross-validation) to predict prognosis. Gene expression profiles of CM cohort were randomly split into two groups: 70% as the training set, and the remaining 30% as the test set. The predictive performance was validated in JAVELIN cohort independently. Gene sets expression levels were estimated using ssGSEA and NES methods. ROC curves were used to evaluate the predictive accuracy for 6-month PFS. Survival plots were created using the Kaplan-Meier estimator, and data were analyzed by log-rank test. Results: 7 signatures were selected as input features including 4 pathways (DNA_repair, IFN_alpha, EMT and angiogenesis) identified in Miao et al. and CM cohorts, together with 3 ICSs (Activated.CD4.T.cell, Activated.CD8.T.cell, and Immature.dendritic.cell) identified in CM cohort. Our model showed promising results for predicting 6-month PFS in CM dataset with AUC of 0.984 in the training set and 0.893 in the test set. The prediction of our model outperformed that based on TMB (AUC 0.655 vs. 0.587), GEP (AUC 0.746 vs. 0.823) and PD-L1 (AUC 0.823 vs. 0.768) both in the training and test sets, while combining our model with biomarkers above improved the prediction drastically with AUC of 0.996 in the training set and 0.935 in the test set. Meanwhile, our model maintained preferable performance for differentiating longer PFS from shorter PFS with p vale of 0.021 in JAVELIN cohort. Conclusions: We proposed a risk model to predict prognosis, in which feature selection based on hallmark pathways and immune cell subtypes. Our model showed excellent performance in predicting PFS in RCC patients undergoing immunotherapy, outperforming other ICB-related biomarkers. While combining our model with TMB, GEP, and PD-L1 was correlated more strongly with survival.

A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma

Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy

A Novel Prognostic Model for Clear Cell Renal Cell Carcinoma with Differentially Expressed Immune-related Lncrna Pairs Based on the Cancer Genome Atlas

The immunotherapy-based combination associated score as a robust predictor for outcome and response to combination of immunotherapy and VEGF inhibitors in renal cell carcinoma

Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs).

Development and Validation of the Prognostic Value of the Immune-Related Genes in Clear Cell Renal Cell Carcinoma

Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer

A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma

Exploring the Immune Landscape of ccRCC: Prognostic Signatures and Therapeutic Implications

Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma

Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer

A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma

Novel Prognosis and Therapeutic Response Model of Immune-Related Lncrna Pairs in Clear Cell Renal Cell Carcinoma.

An immunotherapy response prediction model derived from proliferative CD4<SUP>+</SUP> T cells and antigen-presenting monocytes in ccRCC

Individualized Immune-Related Gene Signature Predicts Immune Status and Oncologic Outcomes in Clear Cell Renal Cell Carcinoma Patients.

Identification of an Independent Immune-genes Prognostic Index for Renal Cell Carcinoma

Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma

Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma